Phylogica Enters Research & Licensing Agreement With Genentech
Phylogica Ltd. recently announced it has extended its collaboration with Genentech, a member of the Roche Group, by entering into a Research and Licensing agreement to discover novel antibiotics. Phylogica will employ its Phylomer drug discovery platform, including its proprietary cell-penetrating peptide discovery technology to identify Phylomer peptides suitable for further
evaluation. Under the terms of the agreement, Phylogica will receive an upfront payment of $500,000. In addition, Phylogica is eligible to receive research, development, and commercialization milestone payments totaling up to US$142 million.
Phylogica’s CEO Dr. Richard Hopkins commented “We are delighted to continue building upon on the success of our initial collaboration with Genentech. This alliance has the potential to address an unmet need for novel antimicrobials to treat bacterial infections, including drug-resistant superbugs.”
Phylogica Ltd. is a biotechnology company based in Perth, Australia, with a world-class
drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics from the most structurally diverse libraries available. The company listed on the ASX in 2005 as a spin-out from the Telethon Kids Institute (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, PA). The company’s drug discovery platform is based on its proprietary Phylomer libraries containing over 400 billion unique natural peptides, which have been optimized by evolutionary selection to adopt
stable drug-like structures. For more information, visit www.phylogica.com.
Total Page Views: 1080
